Latest:
Myeloproliferative Neoplasm Management: Future Directions in Care
Closing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ruben Niesvizky, MD
Latest:
Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma
Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.
Rudi Ross, BS, CCRC
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Rupen Garg, BS
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Russell J. Ledet, PhD, Rachel M. Turner, MA, MS
Latest:
Oncology Fellows: Reminding Ourselves of How Far We've Come
For us, a group of 15 black students at Tulane University School of Medicine (TUSCOM), a visit to the Whitney Plantation in Edgard, Louisiana, was a no-brainer. The process of navigating medical school is pure hell at times, and you need inspiration wherever and whenever you can get it.
Russell S. Crawford, BPharm
Latest:
Denosumab: A Review of Its Pharmacology and Clinical Implications
It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.